Literature DB >> 7525790

Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospective randomized trial.

K Sugimachi1, H Kuwano, H Ide, T Toge, M Saku, Y Oshiumi.   

Abstract

From 1990 to 1991, 40 patients with squamous cell carcinoma of the thoracic oesophagus were admitted to our institutions and chemotherapy (oil Bleomycin p.o. and CDDP d.i.v.) either combined with or without hyperthermia was performed, in a prospective randomized trial carried out to investigate the effects of hyperthermia. The two groups (group A, consisting of 20 patients given chemotherapy alone; and group B, made up of 20 given chemotherapy with hyperthermia) were comparable with regard to various prognostic factors. Following the above treatment regimens, an oesophagectomy was done in 16 and 17 patients from groups A and B, respectively. A subjective improvement of dysphagia was seen in 8 (40.0%), and in 14 patients (70.0%), while a radiographic improvement was recognized in 5 (25.0%) and 10 cases (50.0%) in groups A and B, respectively. In the resected specimen of 16 (group A) and 17 patients (group B), histopathological evidence of the effectiveness of the treatments were recognized in 3 (18.8%) and 7 (41.2%) from groups A and B, respectively. Excluding the cases of superficial carcinoma (T1 tumour), histologic effectiveness of the treatments were recognized in 2 (14.3%) and 7 (58.3%) in groups A and B, respectively (p < 0.05). There was no difference in the occurrence of side effects between the groups. Therefore, the clinical and pathological effects were favourable in the hyperthermia combined with chemotherapy group, especially in the cases with advanced oesophageal cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525790     DOI: 10.3109/02656739409009352

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  12 in total

Review 1.  Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer?

Authors:  Chen-Ting Lee; Thomas Mace; Elizabeth A Repasky
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

Review 2.  Heating technology for malignant tumors: a review.

Authors:  H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

3.  Toward establishment of temperature thresholds for immunological impact of heat exposure in humans.

Authors:  Sarah H Beachy; Elizabeth A Repasky
Journal:  Int J Hyperthermia       Date:  2011       Impact factor: 3.914

4.  Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy.

Authors:  Donald E Thrall; Susan M LaRue; Daohai Yu; Thaddeus Samulski; Linda Sanders; Beth Case; Gary Rosner; Chieko Azuma; Jeannie Poulson; Amy F Pruitt; Wilma Stanley; Marlene L Hauck; Laurel Williams; Paul Hess; Mark W Dewhirst
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

5.  The Kadota Fund International Forum 2004--clinical group consensus.

Authors:  J van der Zee; Z Vujaskovic; M Kondo; T Sugahara
Journal:  Int J Hyperthermia       Date:  2008-03       Impact factor: 3.914

Review 6.  Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia.

Authors:  Adrienne J Peer; Melissa J Grimm; Evan R Zynda; Elizabeth A Repasky
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

7.  Feasibility of concurrent treatment with the scanning ultrasound reflector linear array system (SURLAS) and the helical tomotherapy system.

Authors:  José A Peñagarícano; Eduardo Moros; Petr Novák; Yulong Yan; Peter Corry
Journal:  Int J Hyperthermia       Date:  2008-08       Impact factor: 3.914

Review 8.  [Principles, technology and indication of hyperthermia and part body hyperthermia].

Authors:  M Schlemmer; L H Lindner; S Abdel-Rahman; R D Issels
Journal:  Radiologe       Date:  2004-04       Impact factor: 0.635

9.  Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients.

Authors:  Megan L Steele; Jan Axtner; Antje Happe; Matthias Kröz; Harald Matthes; Friedemann Schad
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-19       Impact factor: 2.629

Review 10.  Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

Authors:  Jan C Peeken; Peter Vaupel; Stephanie E Combs
Journal:  Front Oncol       Date:  2017-06-30       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.